News for CLEARMIND MEDICINE INC (CMNDF)

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA).

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ('Company' or 'SciSparc'), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) ('Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).

Clearmind Medicine (CMND) expands its clinical trial for CMND-100 with a new site at Johns Hopkins University. The trial for CMND-100 aims to evaluate i

Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD), with the activation of additional site at Johns Hopkins University School of Medicine and the enrollment of the first participant at this clinical site.

PR NewswireTORONTO and GLIL YAM, Israel, July 9, 2025 TORONTO and GLIL YAM, Israel, July 9, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company")

Clearmind Medicine (CMND) receives IRB approval from Tel Aviv Sourasky Medical Center for its Phase 1/2a clinical trial. The trial aims to evaluate CMND-100

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CMND), (FSE: CWY0) (”œClearmind” or the "Company"), a clinical-stage biotec

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CMND), (FSE: CWY0) (”œClearmind” or the "Company"), a clinical-stage biotec

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

Clearmind Medicine (CMND) expands its clinical trial for CMND-100 by adding Tel Aviv Sourasky Medical Center as a site. The expansion includes collaboration

**media[661852]**

**media[653219]**

Patent publication in Europe strengthens Clearmind's global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (

\n SciSparc Ltd. (SPRC) collaborates with Clearmind Medicine Inc. on an innovative addiction treatment. The partnership focuses on a patent application in

Clearmind Medicine Inc. (CMND) has taken a significant step forward in addressing eating disorders by submitting an international patent application for a novel

Clearmind Medicine (CMND) files an international patent application for a novel treatment targeting eating disorders. The treatment combines 3-Methylmet

Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CMND), (FSE: CWY0) (”œClearmind” or the "Company"), a clinical-stage biotec

**media[605557]**